Stock SUVENPHAR SUVEN PHARMACEUTICALS LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Suven Pharmaceuticals Limited

Equities

SUVENPHAR

INE03QK01018

Pharmaceuticals

End-of-day quote NSE India S.E.
Other stock markets
 06:00:00 2024-06-05 pm EDT 		5-day change 1st Jan Change
635.6 INR +0.81% Intraday chart for Suven Pharmaceuticals Limited +0.55% -12.07%
May. 30 Transcript : Suven Pharmaceuticals Limited, Q4 2024 Earnings Call, May 30, 2024
May. 30 Suven Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024 CI

Valuation

Fiscal Period: March 2020 2021 2022 2023 2024 2025
Capitalization 1 25,590 126,468 157,436 161,789 161,789 -
Enterprise Value (EV) 1 25,590 126,468 157,436 120,256 161,789 161,789
P/E ratio 16.1 x 34.9 x 34.7 x 29.2 x 48.3 x 47.4 x
Yield - 0.4% 0.32% 0.37% 0.28% 0.24%
Capitalization / Revenue - 12.5 x 11.9 x 8.97 x 14.8 x 14 x
EV / Revenue - 12.5 x 11.9 x 8.97 x 14.8 x 14 x
EV / EBITDA - 28.7 x 27.2 x 21.2 x 36.8 x 34.3 x
EV / FCF - 176 x 61.8 x 72.8 x - -
FCF Yield - 0.57% 1.62% 1.37% - -
Price to Book - 10.7 x 10.3 x 6.93 x 7.97 x 7.04 x
Nbr of stocks (in thousands) 254,565 254,565 254,565 254,565 254,565 -
Reference price 2 100.5 496.8 618.4 635.6 635.6 635.6
Announcement Date 6/18/20 6/8/21 5/9/22 5/25/23 - -
1INR in Million2INR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: March 2020 2021 2022 2023 2024 2025
Net sales 1 - 10,097 13,202 13,403 10,898 11,528
EBITDA 1 - 4,405 5,794 5,665 4,392 4,716
EBIT 1 - 4,088 6,738 5,652 4,360 4,580
Operating Margin - 40.49% 51.04% 42.17% 40.01% 39.73%
Earnings before Tax (EBT) 1 - 4,139 6,676 5,597 4,484 4,538
Net income 1 - 3,623 4,538 4,113 3,342 3,404
Net margin - 35.89% 34.37% 30.69% 30.66% 29.53%
EPS 2 6.230 14.23 17.83 16.16 13.15 13.40
Free Cash Flow 1 - 720.4 2,548 1,651 - -
FCF margin - 7.13% 19.3% 12.32% - -
FCF Conversion (EBITDA) - 16.35% 43.98% 29.15% - -
FCF Conversion (Net income) - 19.88% 56.15% 40.15% - -
Dividend per Share 2 - 2.000 2.000 2.350 1.750 1.500
Announcement Date 6/18/20 6/8/21 5/9/22 5/25/23 - -
1INR in Million2INR
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: March 2021 Q2 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3
Net sales 1 2,377 2,749 2,592 2,638 3,060 3,916 3,638 3,388 2,784 3,538 3,694 3,431 3,025 3,045
EBITDA 1 984.9 1,381 936.9 1,146 1,218 1,860 1,570 1,509 998.8 1,467 1,691 1,416 - 1,208
EBIT - - - - - - - - - - - - - -
Operating Margin - - - - - - - - - - - - - -
Earnings before Tax (EBT) - - - - - - - - - - - - - -
Net income 1 740.8 1,136 831.2 1,051 969.8 1,601 916.7 1,075 720.6 1,077 1,240 1,044 913 906
Net margin 31.16% 41.33% 32.07% 39.83% 31.69% 40.88% 25.19% 31.74% 25.88% 30.45% 33.56% 30.43% 30.18% 29.75%
EPS - - - 4.130 3.810 - 3.600 - - - - - - -
Dividend per Share - - - - - - - - - - - - - -
Announcement Date 10/30/20 2/10/21 6/8/21 8/16/21 11/6/21 2/8/22 5/9/22 8/8/22 11/8/22 2/6/23 5/25/23 - - -
1INR in Million
Estimates

Balance Sheet Analysis

Fiscal Period: March 2021 2022 2023 2024 2025
Net Debt - - - - -
Net Cash position - - - - -
Leverage (Debt/EBITDA) - - - - -
Free Cash Flow 1 720 2,548 1,651 - -
ROE (net income / shareholders' equity) 35.8% 33.5% 25.2% 17.7% 15.8%
ROA (Net income/ Total Assets) - - - - -
Assets 1 - - - - -
Book Value Per Share 2 46.40 60.00 68.20 79.70 90.30
Cash Flow per Share - - - - -
Capex 1 1,108 752 2,858 1,585 1,800
Capex / Sales 10.98% 5.7% 21.32% 14.54% 15.61%
Announcement Date 6/8/21 5/9/22 5/25/23 - -
1INR in Million2INR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Suven Pharmaceuticals Limited

Trading Rating
Investor Rating
ESG Refinitiv
D-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
2
Last Close Price
635.6 INR
Average target price
670.5 INR
Spread / Average Target
+5.50%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
SUVEN PHARMACEUTICALS LIMITED Stock Suven Pharmaceuticals Limited
-12.07% 1.92B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+43.64% 749B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+39.42% 605B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.58% 351B
MERCK & CO., INC. Stock Merck & Co., Inc.
+19.72% 328B
ABBVIE INC. Stock AbbVie Inc.
+8.78% 292B
NOVARTIS AG Stock Novartis AG
+11.92% 216B
ROCHE HOLDING AG Stock Roche Holding AG
-2.62% 214B
PFIZER, INC. Stock Pfizer, Inc.
+0.03% 167B
AMGEN INC. Stock Amgen Inc.
+6.13% 165B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. SUVENPHAR Stock
  4. Financials Suven Pharmaceuticals Limited